Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAt 7.2mg, Wegovy reaches its highest approved maintenance dose, and the side effect picture is broadly similar to lower strengths — predominantly gastrointestinal, most noticeable after each dose increase, and for most people manageable and temporary. The NHS patient information for semaglutide sets out the full profile, and it applies across the titration schedule. What differs at 7.2mg is context: you will have spent several months stepping up through earlier doses, so your body has already had time to adjust. That said, 7.2mg is the strongest semaglutide dose approved in the UK, and some people do experience a return of symptoms (particularly nausea) after the final increase. These are prescription-only medicines, and a GPhC-registered prescriber reviews every person's medical history before treatment begins and at each stage of dose progression.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy's titration schedule means most people who reach 7.2mg have already lived with the 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg doses. That experience is genuinely useful, you will already know how your body signals nausea or digestive discomfort, and how quickly things tend to settle for you personally. The pattern at 7.2mg tends to follow the same rhythm: the days immediately after an injection at a new dose are the likeliest window for nausea, loose stools, constipation, indigestion or belching. Fatigue and mild headache also appear in the common side effect list. For many people these sensations are milder at 7.2mg than they were at the very first few doses, simply because the gut has had months to adapt to semaglutide's mechanism of slowing gastric emptying.
Eating smaller portions, avoiding very rich or fatty food around injection day, and staying well hydrated all help, practical habits most people on the titration schedule have already found by this point. If symptoms feel significantly worse than earlier steps, that is worth raising with your prescriber rather than waiting it out, and our dedicated page on Wegovy 7.2mg side effects sets out in detail what to expect at this specific dose. You can explore how side effects vary across the dose schedule on our guide to Wegovy doses.
Alongside the common GI effects sits a smaller group of symptoms that always warrant prompt action, regardless of which dose you are on. Acute pancreatitis is the clearest example. In January 2026 the MHRA issued a Drug Safety Update on GLP-1 medicines specifically because pancreatitis (though infrequent) can be serious. The signal to act on is severe, persistent abdominal pain that may radiate into the back, with or without vomiting. If you experience that, stop taking the medicine and get urgent medical help. It should not be confused with the mild stomach discomfort that is common and usually settles on its own.
Gallbladder symptoms are another category to know: pain in the upper right abdomen, especially after eating, can indicate gallstones, which occur more frequently with rapid weight loss generally. Signs of a significant allergic reaction (widespread rash, difficulty breathing, swelling of the face or throat) require emergency attention. If severe vomiting or diarrhoea continues for more than a day or two, dehydration becomes a real concern and puts strain on the kidneys; contact your GP or call 111. For a fuller picture of side effects across the earlier doses, our page on Wegovy 2.4mg side effects covers the main maintenance-dose profile in detail.
The clearest rule is this: if something feels severe, persistent or simply wrong, do not dismiss it because you have read that GI effects are common. The following are reasons to contact a healthcare professional promptly, your GP, NHS 111, or our aftercare team if you are a nume patient. Severe stomach pain reaching the back (possible pancreatitis), signs of an allergic reaction, significant dehydration from prolonged vomiting or diarrhoea, upper abdominal pain that could suggest gallbladder involvement, and any sudden changes in vision if you have diabetes in your history, all of these fall into act-now territory rather than wait-and-see.
You can also report any suspected side effect directly to the MHRA through the Yellow Card scheme, which is open to patients. Reporting matters: it contributes to the ongoing post-market surveillance that keeps prescribing guidance current for everyone. The 7.2mg dose carries a Black Triangle (▼) designation, meaning the MHRA actively collects additional safety data on it, your report is not a complaint but a contribution. If you are wondering how the side effect profile at 7.2mg compares with what was reported at 1.7mg earlier in the schedule, our Wegovy 1.7mg side effects page gives that context. And if you want to understand what to expect when you first step up from the starting dose, our guide to Wegovy 1mg side effects walks through the early titration experience in detail. If the overall picture of Wegovy (including how this dose fits into the licensed approval) is what you are weighing up, the Wegovy overview covers it from the beginning.
Our prescribers discuss side effects, medical history and suitability as part of every consultation, not as a box-tick, but because these conversations genuinely change the advice given. A question our prescribers hear most weeks is whether past GI problems rule someone out; often they do not, but the answer depends on the full picture. If you want to talk through whether treatment is right for you, checking your eligibility with a free consultation is the place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.